<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35488355</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1752-1947</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of medical case reports</Title>
          <ISOAbbreviation>J Med Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Aggressive giant prolactinoma: a case report.</ArticleTitle>
        <Pagination>
          <StartPage>170</StartPage>
          <MedlinePgn>170</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">170</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13256-022-03390-y</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Managing treatment-resistant aggressive giant prolactinoma can be challenging, as the diagnosis is often complex, and treatment beyond dopamine agonists, surgery, and radiotherapy is limited.</AbstractText>
          <AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 21-year-old Malay woman first presented to our hospital at the age of 16 years with 1-year history of reduced vision and 2 years of amenorrhea. Her baseline prolactin level was 255,894 µIU/mL with secondary hypogonadism, and pituitary magnetic resonance imaging revealed a giant prolactinoma (2.8 × 3.2 × 4.2 cm<sup>3</sup>) with suprasellar extension and optic chiasmal compression. She was initially treated with cabergoline, and reductions in the prolactin level and tumor mass were achieved, leading to vision improvement and resumption of normal menstruation. However, she developed recurrent tumor growth and hyperprolactinemia, causing relapse of symptoms, and she needed surgery. Eventually, despite three tumor debulking surgeries and escalation of cabergoline doses up to 1 mg/day, her tumor progressed with aggressive characteristics. Following a multidisciplinary meeting, the patient is initiated on temozolomide therapy after considering the long-term side effects of radiotherapy in her case.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This case highlights the importance of early identification of treatment-resistant prolactinoma and the need for a multidisciplinary approach in managing aggressive prolactinoma in young patients, particularly regarding timely implementation of temozolomide therapy.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Borhan</LastName>
            <ForeName>Marisa Khatijah</ForeName>
            <Initials>MK</Initials>
            <Identifier Source="ORCID">0000-0003-4053-0930</Identifier>
            <AffiliationInfo>
              <Affiliation>Endocrinology Unit, Medical Department, Sarawak General Hospital, Kuching Sarawak, Malaysia. mkborhan@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tan</LastName>
            <ForeName>Florence Hui Sieng</ForeName>
            <Initials>FHS</Initials>
            <AffiliationInfo>
              <Affiliation>Endocrinology Unit, Medical Department, Sarawak General Hospital, Kuching Sarawak, Malaysia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Med Case Rep</MedlineTA>
        <NlmUniqueID>101293382</NlmUniqueID>
        <ISSNLinking>1752-1947</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>9002-62-4</RegistryNumber>
          <NameOfSubstance UI="D011388">Prolactin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LL60K9J05T</RegistryNumber>
          <NameOfSubstance UI="D000077465">Cabergoline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YF1K15M17Y</RegistryNumber>
          <NameOfSubstance UI="D000077204">Temozolomide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077465" MajorTopicYN="N">Cabergoline</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010911" MajorTopicYN="Y">Pituitary Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011388" MajorTopicYN="N">Prolactin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015175" MajorTopicYN="Y">Prolactinoma</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077204" MajorTopicYN="N">Temozolomide</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Aggressive prolactinoma</Keyword>
        <Keyword MajorTopicYN="N">Case report</Keyword>
        <Keyword MajorTopicYN="N">Giant prolactinoma</Keyword>
        <Keyword MajorTopicYN="N">Temozolomide</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>0</Hour>
          <Minute>2</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35488355</ArticleId>
        <ArticleId IdType="pmc">PMC9055719</ArticleId>
        <ArticleId IdType="doi">10.1186/s13256-022-03390-y</ArticleId>
        <ArticleId IdType="pii">10.1186/s13256-022-03390-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Shimon I. Giant prolactinomas. Neuroendocrinology. 2019;109(1):51–56. doi: 10.1159/000495184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000495184</ArticleId>
            <ArticleId IdType="pubmed">30404098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maiter D, Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol. 2014;170(6):R213–R227. doi: 10.1530/EJE-14-0013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-14-0013</ArticleId>
            <ArticleId IdType="pubmed">24536090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vroonen L, Jaffrain-Rea ML, Petrossians P, et al.  Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients [published correction appears in Eur J Endocrinol. 2012 Dec;167(6):887] Eur J Endocrinol. 2012;167(5):651–662. doi: 10.1530/EJE-12-0236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-12-0236</ArticleId>
            <ArticleId IdType="pubmed">22918301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raverot G, Burman P, McCormack A, et al.  European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178(1):G1–G24. doi: 10.1530/EJE-17-0796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-17-0796</ArticleId>
            <ArticleId IdType="pubmed">29046323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimon I, Sosa E, Mendoza V, et al.  Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas. Pituitary. 2016;19(4):429–436. doi: 10.1007/s11102-016-0723-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-016-0723-4</ArticleId>
            <ArticleId IdType="pubmed">27138902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ceccato F, Regazzo D, Barbot M, et al.  Early recognition of aggressive pituitary adenomas: a single-centre experience. Acta Neurochir (Wien) 2018;160(1):49–55. doi: 10.1007/s00701-017-3396-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00701-017-3396-5</ArticleId>
            <ArticleId IdType="pubmed">29170844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu JK, Couldwell WT. Contemporary management of prolactinomas. Neurosurg Focus. 2004;16(4):e2. doi: 10.3171/foc.2004.16.4.3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/foc.2004.16.4.3</ArticleId>
            <ArticleId IdType="pubmed">15191331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab. 2002;87(7):3180–3186. doi: 10.1210/jcem.87.7.8645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem.87.7.8645</ArticleId>
            <ArticleId IdType="pubmed">12107221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han YL, Chen DM, Zhang C, Pan M, Yang XP, Wu YG. Retrospective analysis of 52 patients with prolactinomas following endoscopic endonasal transsphenoidal surgery. Medicine (Baltimore) 2018;97(45):e13198. doi: 10.1097/MD.0000000000013198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000013198</ArticleId>
            <ArticleId IdType="pmc">PMC6250442</ArticleId>
            <ArticleId IdType="pubmed">30407358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halevy C, Whitelaw BC. How effective is temozolomide for treating pituitary tumours and when should it be used? Pituitary. 2017;20(2):261–266. doi: 10.1007/s11102-016-0745-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-016-0745-y</ArticleId>
            <ArticleId IdType="pubmed">27581836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almalki MH, Aljoaib NN, Alotaibi MJ, et al.  Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. Hormones (Athens) 2017;16(2):139–149. doi: 10.14310/horm.2002.1729.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14310/horm.2002.1729</ArticleId>
            <ArticleId IdType="pubmed">28742502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCormack A, Dekkers OM, Petersenn S, et al.  Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178(3):265–276. doi: 10.1530/EJE-17-0933.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-17-0933</ArticleId>
            <ArticleId IdType="pubmed">29330228</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
